In summary, this study suggests the potential of heterobivalent radioligand [99mTc]-HYNIC-cRDGfk-NPY to target breast tumors by targeting more than one biomarker as an agent for SPECT imaging. This evidence concerns the gene NPY and breast neoplasm.